These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 32113852)

  • 1. Insulin degludec allows for better glycaemic control with a lower risk of hypoglycaemia in patients with chronic kidney disease and type 2 diabetes.
    Dolores García de Lucas M; Avilés Bueno B; Rivas Ruiz F; Olalla Sierra J
    Diabetes Res Clin Pract; 2020 Apr; 162():108094. PubMed ID: 32113852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design.
    Agesen RM; Alibegovic AC; Andersen HU; Beck-Nielsen H; Gustenhoff P; Hansen TK; Hedetoft C; Jensen T; Juhl CB; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
    BMC Endocr Disord; 2019 Jul; 19(1):78. PubMed ID: 31337371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes.
    Khunti K; Cos X; Rutten G
    Prim Care Diabetes; 2014 Jul; 8(2):119-25. PubMed ID: 24207030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.
    Kerlan V; Gouet D; Marre M; Renard É
    Ann Endocrinol (Paris); 2013 Dec; 74(5-6):487-90. PubMed ID: 23978337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes.
    Chatterjee S; Khunti K; Davies MJ
    Drugs; 2019 Feb; 79(2):173-186. PubMed ID: 30623349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycaemic control in insulin requiring diabetes patients receiving exclusive enteral tube feeding in an acute hospital setting.
    Murphy PM; Moore E; Flanagan DE
    Diabetes Res Clin Pract; 2014 Mar; 103(3):426-9. PubMed ID: 24462281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes.
    Marre M; Pinget M; Gin H; Thivolet C; Hanaire H; Robert JJ; Fontaine P
    Diabetes Metab; 2009 Dec; 35(6):469-75. PubMed ID: 19914118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
    Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
    Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
    Vedtofte L; Knop FK; Vilsbøll T
    Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between the extent of urinary albumin excretion and glycaemic variability indices measured by continuous glucose monitoring.
    Jin SM; Kim TH; Oh S; Baek J; Joung JY; Park SM; Cho YY; Sohn SY; Hur KY; Lee MS; Lee MK; Kim JH
    Diabet Med; 2015 Feb; 32(2):274-9. PubMed ID: 25307609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: Analysis of real-life data from the DPV registry from Germany and Austria.
    Bohn B; Kerner W; Seufert J; Kempe HP; Jehle PM; Best F; Füchtenbusch M; Knauerhase A; Hofer M; Rosenbauer J; Holl RW;
    Diabetes Res Clin Pract; 2016 May; 115():31-8. PubMed ID: 27242120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
    Pratley RE; Husain M; Lingvay I; Pieber TR; Mark T; Saevereid HA; Møller DV; Zinman B;
    Cardiovasc Diabetol; 2019 Nov; 18(1):156. PubMed ID: 31729990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.
    Berard L; MacNeill G
    Can J Diabetes; 2015 Feb; 39(1):4-9. PubMed ID: 25065475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin degludec + liraglutide (Xultophy°) in type 2 diabetes.
    Prescrire Int; 2017 May; 26(182):121. PubMed ID: 30730669
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.
    Gallegos Aragon K; Elmaoued AA; Pham NT; Conklin JR; Ray GM
    Cardiol Rev; 2019; 27(5):260-266. PubMed ID: 31393288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin degludec. Uncertainty over cardiovascular harms.
    Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
    Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diabetes mellitus type 1 and 2. Flexible therapy with insulin degludec].
    Rausch R
    Med Monatsschr Pharm; 2014 Jul; 37(7):273-4. PubMed ID: 25065174
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypoglycemia, chronic kidney disease, and diabetes mellitus.
    Alsahli M; Gerich JE
    Mayo Clin Proc; 2014 Nov; 89(11):1564-71. PubMed ID: 25305751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.